Search

A recent report from the Autonomous University Barcelona discusses new research on BCR-ABL tyrosine kinase inhibitors. The study focuses on the quantification of histone H1 subtypes using targeted proteomics. Histone H1 is involved in the regulation of chromatin structure, and alterations in the protein levels of different H1 subtypes have been observed in cancer. The researchers developed a mass spectrometry-based assay for the quantification of H1 subtypes and found differences in the H1 complement in chronic myeloid leukemia patients between responders and non-responders to imatinib therapy. Further research is needed to determine if the H1 content or subtype composition could help predict imatinib response. [Extracted from the article]

A study conducted by researchers at Qingdao University in Shandong, China, explores the role of circular RNA 0080145 (circ_0080145) in the resistance of chronic myeloid leukemia (CML) to imatinib (IM) therapy. The study found that circ_0080145 is upregulated in IM-resistant CML patients and cells. Silencing circ_0080145 suppressed IM resistance, cell growth, and glycolysis, and induced apoptosis in IM-resistant CML cells. The study suggests that circ_0080145 contributes to IM resistance by modulating the miR-326/PPFIA1 axis, providing a potential avenue for CML therapy. [Extracted from the article]

A recent study conducted at the All India Institute of Medical Sciences (AIIMS) compared the efficacy of hydroxyurea (HU) combined with imatinib versus imatinib monotherapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP) patients. The study found that the addition of upfront HU did not significantly improve hematological response and early molecular response (EMR) at 3 months. However, the researchers suggest that further long-term studies with a larger sample size could be undertaken to explore the potential benefits of HU as an adjunctive therapy for initial cytoreduction in certain CML patients. [Extracted from the article]

A recent study conducted in Chandigarh, India, examined the effects of imatinib mesylate (IM) on the reproductive system of female patients with chronic myeloid leukemia (CML). The study found no significant differences in ovarian reserve parameters, such as menstrual cycle characteristics, anti-Mullerian hormone (AMH) levels, and antral follicle count (AFC), between CML patients receiving IM therapy and newly diagnosed patients who had not yet started treatment. However, the study did find that patients taking IM for at least one year had a significantly lower age at menopause compared to the control group, indicating a potential risk of early iatrogenic menopause. Further investigation through larger studies is needed to confirm these findings. [Extracted from the article]

A study conducted at Nehru Hospital in Chandigarh, India, explored the impact of T-regulatory cells (Tregs) and PD-1 + CD8 T-cells in patients with chronic myeloid leukemia (CML) who were treated with imatinib mesylate. The study found that CML patients had higher levels of Tregs and PD-1 + CD8 T-cells compared to healthy controls, but these levels decreased significantly after three months of imatinib treatment. The researchers suggest that these findings indicate the potential for immunotherapy as a promising approach to managing immune exhaustion in CML patients. The study has been peer-reviewed and published in the Indian Journal of Hematology and Blood Transfusion. [Extracted from the article]

A study conducted by researchers at the General Hospital of Ningxia Medical University has investigated the role of SPRY4 intronic transcript 1 (SPRY4-IT1) in gastrointestinal stromal tumors (GIST). The study found that SPRY4-IT1, a long non-coding RNA, is highly expressed in GIST and enhances the activation and expression of KIT, a proto-oncogene. This leads to increased cell survival, proliferation, and resistance to imatinib, a targeted therapeutic drug for GIST. The findings provide new insights into the regulation of KIT signaling and the resistance of GIST to targeted therapy. [Extracted from the article]

The article from the Second Affiliated Hospital of Chongqing Medical University highlights the role of BCL6 in chronic myeloid leukemia (CML) treatment resistance. The study found that high levels of BCL6 in CML cells are linked to resistance to imatinib, but targeting BCL6 with specific inhibitors like BI-3812 can enhance the effectiveness of tyrosine kinase inhibitors (TKIs) and overcome resistance.

The article focuses on a newly issued patent concerning methods for treating gastrointestinal stromal tumors (GISTs). Topics include the prevalence and genetic mutations associated with GISTs, the role of receptor tyrosine kinases (KIT and PDGFRA) in their oncogenic behavior, and the evolution of treatment strategies from surgical approaches to targeted therapies based on molecular understanding.

The article focuses on the issuance of a patent to Deciphera Pharmaceuticals for new methods of treating gastrointestinal stromal tumors (GIST). Topics include the prevalence and genetic mutations associated with GIST, the evolution of targeted therapies such as imatinib, and the challenges posed by drug resistance due to secondary mutations.

The article focuses on the treatment of a rare BRAF V600E mutant gastrointestinal stromal tumor (GIST) with dabrafenib. Topics include the limitations of standard GIST therapies, the effectiveness of dabrafenib in treating BRAF-mutant GIST, and the importance of molecular testing in personalizing treatment strategies for this tumor subtype.

The article provides information on the patent application "Methods of Treating Gastrointestinal Stromal Tumors," filed by the inventors Xiaoyan Li and Jing Wang on September 11, 2023 and was made available online on August 8, 2024. Topics include a discussion on gastrointestinal stromal tumors (GIST), inventors' summary information for the patent application, and the claims supplied by the inventors.

Researchers at Jagiellonian University have published a report on the use of anticancer agents, specifically focusing on the drug imatinib. Imatinib is a kinase inhibitor commonly used to block cancer growth, but it can have serious side effects, including congestive cardiac failure. The researchers explored the use of biocompatible metal-organic framework (MOF) materials as carriers for imatinib, which effectively delivered the drug as an anticancer agent while minimizing cardiotoxicity. The study found that the MOF carriers reduced the adverse effects of imatinib without compromising its effectiveness. This research provides valuable insights into potential strategies for improving cancer therapy. [Extracted from the article]

A recent study conducted at the Central Research Laboratory has developed a simple, sensitive, and accurate method for estimating the concentration of Imatinib mesylate in pharmaceutical dosage forms. The method involves the formation of colored ion pair complexes with thiocyanate ions, which are then quantitatively extracted in chloroform. The absorbance values are measured at 618 nm, and the method has been validated statistically. The study concludes that this method is useful for routine estimation of Imatinib mesylate in tablets. For more information, readers can refer to the article "Determination of Imatinib mesylate from Pharmaceutical Dosage Form by extractive ion pair complex colorimetric Method" published in the Asian Journal of Research in Chemistry. [Extracted from the article]

A patent application titled "Dosing Regimens" has been published online by the US Patent and Trademark Office. The inventors propose a method of treating BCR-ABL-mediated diseases or disorders, such as chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML), by administering a pharmaceutical combination of asciminib and another therapeutic agent. The patent application also describes specific dose regimens and pharmaceutical combinations for the treatment of these diseases. The compound asciminib, also known as Compound I, is an inhibitor of the tyrosine kinase activity of the BCR-ABL1 protein. The inventors suggest that this compound, used in combination with other therapeutic agents, may prevent the development of drug resistance. [Extracted from the article]

A new report from researchers at St. Louis University discusses the clinicopathologic features of a case of pityriasis rosea-like drug eruption secondary to imatinib, a drug used in the treatment of chronic myeloid leukemia. Pityriasis rosea is a skin condition characterized by erythematous and scaly lesions, and drug eruptions that resemble this condition have been reported. The distinction between classic pityriasis rosea and drug-related eruptions is important for management purposes. The study found that while the clinical morphology of the drug-related eruption mimics classic pityriasis rosea, unique histopathologic findings can aid in distinguishing between the two. [Extracted from the article]

A study conducted by the Institute for Cancer Research and Treatment (IRCCS) in Pavia, Italy, has investigated the effects of imatinib, a BCR-ABL tyrosine kinase inhibitor, on pulmonary fibrosis. The researchers used Precision Cut Lung Slices (PCLSs) as an ex vivo model to evaluate the anti-remodeling activity of imatinib. The results showed that imatinib significantly decreased the expression of markers associated with fibrosis, but also demonstrated toxicity towards unstimulated cells. The study suggests that while imatinib has anti-remodeling activity, its direct delivery to alveolar epithelial cells may have potential toxicity. [Extracted from the article]

A recent study conducted in Chandigarh, India, examined the cardiovascular effects of imatinib, a drug used in the treatment of chronic myeloid leukemia (CML). The study included 110 patients with CML, divided into a treatment-naive group and a group receiving imatinib therapy for at least one year. The results showed that imatinib may potentially cause cardiac dysfunction in patients with CML. However, further large-scale trials are needed to validate these findings. This research provides valuable insights into the effects of imatinib on the cardiovascular system in CML patients. [Extracted from the article]

According to a preprint abstract from biorxiv.org, researchers have found that the anticancer drug imatinib mesylate (Gleevec) and a chemically distinct compound, DV2-103, can reduce the production of beta-amyloid, a protein associated with Alzheimer's disease. These compounds work by altering the metabolism of amyloid precursor protein (APP) through multiple pathways, including inhibiting BACE1 and gamma-secretase enzymes and stimulating autophagy. The researchers synthesized and tested different isomers of imatinib to understand how structurally diverse compounds can have similar effects on APP metabolism. This research has not yet undergone peer review. [Extracted from the article]

A new report from Chongqing Medical University in China discusses the potential of mTOR inhibition as a therapeutic target for imatinib-resistant patients with chronic myeloid leukemia (CML). Imatinib is a commonly used therapy for CML, but resistance can occur. The study found that mTOR, a regulator of cell growth, is upregulated in imatinib-resistant cells. Inhibition of mTOR with AZD2014 led to growth inhibition and enhanced autophagy, suggesting that mTOR could be a potential target to overcome imatinib resistance in a BCR-ABL1 independent manner. The research was supported by the National Natural Science Foundation of China. [Extracted from the article]

A patent has been issued for methods of treating gastrointestinal stromal tumors (GIST) by administering ripretinib or a pharmaceutically acceptable salt thereof. GISTs are rare tumors that occur in the gastrointestinal tract, with mutations in KIT and PDGFRA genes being common. Imatinib is a commonly used treatment, but resistance can develop. The patent describes various dosing regimens for ripretinib in patients whose tumors have progressed or who are intolerant to imatinib. The methods aim to provide effective treatment options for GIST patients. [Extracted from the article]

A patent has been issued to Deciphera Pharmaceuticals LLC for methods of treating gastrointestinal stromal tumors (GIST). GISTs are rare tumors that occur in the gastrointestinal tract, with the majority of cases caused by mutations in the KIT or PDGFRA genes. The patent describes the use of ripretinib, a tyrosine kinase inhibitor, as a potential treatment for advanced GIST in patients who have progressed from or are intolerant to previous therapies such as imatinib. The patent outlines various dosing regimens for ripretinib and claims that the treatment can provide about 15 months of survival in patients who have received at least 4 lines of prior therapy. [Extracted from the article]

A patent has been issued to Deciphera Pharmaceuticals LLC for methods of treating gastrointestinal stromal tumors (GIST). GISTs are rare tumors that occur in the gastrointestinal tract, with the majority of cases caused by mutations in the KIT or PDGFRA genes. The patent describes a method of treating advanced GIST by administering ripretinib, a tyrosine kinase inhibitor, to patients who have previously been treated with imatinib. The treatment aims to provide more than 3 months of progression-free survival in patients. The patent also includes various dosage regimens for ripretinib administration. [Extracted from the article]

A recent study conducted at Queen Elizabeth Hospital Birmingham has found that Imatinib Mesylate is highly effective in treating chronic myeloid leukemia (CML) at the hematological level. The study included 46 patients within the chronic phase of CML who were given 400mg of Imatinib. After three months of therapy, 91.3% of patients achieved a complete hematological response. The study concludes that Imatinib Mesylate can be considered the drug of first choice in treating CML in the chronic phase. [Extracted from the article]

A study conducted by researchers at Zhejiang University in Hangzhou, China, has found that the protein Cofilin (CFL1) plays a role in the response of chronic myeloid leukemia (CML) patients to imatinib therapy. The study evaluated the expression of CFL1 in CML patients and healthy controls, and found that lower CFL1 expression before treatment was associated with a better response to imatinib therapy. The researchers concluded that imatinib affects the remodeling of F-actin in CML patients by regulating CFL1 expression and activity. This research provides valuable insights into the potential use of CFL1 as a predictive marker for imatinib therapy in CML patients. [Extracted from the article]

A report from the Knight Cancer Institute in Portland, Oregon discusses the use of adjuvant imatinib therapy in patients with high-risk resected gastrointestinal stromal tumors (GIST). The study found that while adjuvant imatinib therapy improved recurrence-free survival (RFS), it did not have a clear impact on ultimate recurrence, overall survival (OS), or time to imatinib resistance (TTIR). The researchers suggest that additional studies are needed to determine the benefit of adjuvant therapy versus initiating therapy at first radiographic recurrence. This research has been peer-reviewed and published in the Journal of Surgical Oncology. [Extracted from the article]

A recent study conducted by researchers at Ajman University in the United Arab Emirates explored the potential of repurposing FDA-approved drugs as inhibitors for histone deacetylase 3 (HDAC3), a target in the treatment of complex diseases, including cancer. Through structure-based virtual screening and molecular dynamics simulations, the researchers identified two drugs, Imatinib and Carpipramine, that demonstrated strong affinity and specificity for HDAC3. The study suggests that these drugs may hold significant therapeutic potential for the treatment of various diseases, particularly cancer. Further research is needed to explore their efficacy in clinical settings. [Extracted from the article]

A study conducted at the Federal University Para in Belem, Brazil, explored the genetic factors that contribute to resistance to imatinib therapy in patients with Chronic Myeloid Leukemia (CML). The researchers investigated 129 CML patients who were treated with imatinib and found that a specific genetic variant in the ULK3 gene, known as rs2290573, may be associated with treatment resistance. The study highlights the importance of predictive biomarkers in guiding treatment decisions for CML patients, ultimately improving their quality of life and treatment efficacy. [Extracted from the article]

A study conducted by the School of Pharmacy in Lianyungang, People's Republic of China, has discovered sixteen novel imamine-1,3,5-triazine derivatives that show potential as anti-cancer agents. These compounds were tested against breast, cervical, and kidney cancer cells and demonstrated better anticancer activity than imatinib, a commonly used cancer drug. Compound 4f, in particular, showed strong inhibitory effects on the migration, invasion, and adhesion of breast cancer cells, as well as inhibiting the in vivo proliferation of tumor xenografts. Further research is needed, but compound 4f may be a promising drug candidate for cancer treatment. [Extracted from the article]

A study conducted at the Medical University of Plovdiv in Bulgaria analyzed the pharmacoeconomic effectiveness of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML). The study compared the costs and outcomes of different TKIs used in first- and second-line therapy for CML patients. The research found that the hematologists at the University Center in Plovdiv achieved good therapeutic and pharmacoeconomic efficiency in the treatment of CML patients, adhering to recommended guidelines. The study's findings can help improve diagnostic and therapeutic standards and optimize the use of limited healthcare resources in Bulgaria. [Extracted from the article]

A recent study conducted at the Medical University of Gdansk in Poland explored the potential neuroprotective effects of a non-covalent conjugate of imatinib with TP10 in the context of Parkinson's disease. Imatinib, a tyrosine kinase inhibitor, has shown promise in preclinical animal models of the disease by inhibiting c-Abl, a non-receptor tyrosine kinase associated with oxidative stress. However, the poor distribution of imatinib within the brain tissue prompted researchers to test a conjugate of imatinib with TP10, which has high translocation activity across cell membranes. The experiments conducted on HT-22 neuronal cells indicated that the conjugate reduced oxidative stress, apoptosis, and mortality more effectively than imatinib alone, without activating the ABCB1 protein. These findings suggest that the imatinib+TP10 conjugate may have potential as a neuroprotective treatment for Parkinson's disease and warrant further in vivo research. [Extracted from the article]

A study conducted by researchers at Universite Paris Cite has found that certain genetic variants are associated with the plasma concentration of the drug imatinib in patients with chronic myeloid leukemia (CML). The researchers analyzed the genetic data of CML patients who were treated with imatinib and identified 50 single nucleotide polymorphisms (SNPs) that were associated with imatinib plasma concentration. These SNPs were found in genes encoding proteins involved in cell adhesion, transcription/translation, and the diffusion and transit of imatinib through membranes or epithelial barriers. The study suggests that genetic factors may contribute to the variability in imatinib plasma concentration among CML patients. [Extracted from the article]

A patent has been issued for a combination therapy involving liposomal antisense oligonucleotides for the treatment of cancer. The therapy targets the Grb2 nucleic acid and utilizes a Bcr-Abl tyrosine kinase inhibitor. The patent describes the background of chronic myelogenous leukemia (CML) and the genetic rearrangement that leads to the activation of the RAS and PI3K pathways. The invention aims to provide more effective treatments for CML patients who are in accelerated or blast phase or who are resistant to tyrosine kinase inhibitors. The patent includes methods of administration and dosage recommendations for the therapy. [Extracted from the article]

A recent study conducted by researchers at Army Medical University in Chongqing, China, explored the efficacy and toxicity of combining imatinib mesylate and atorvastatin calcium in the treatment of steroid-refractory chronic graft-versus-host disease (SR-cGVHD). The study involved 60 patients with SR-cGVHD and found that the combination therapy was effective in treating the disease and reducing target organ injury, particularly liver damage. The study also observed changes in T-cell subsets and adverse events associated with the treatment. The findings suggest that T-cell regulatory function may play a crucial role in the treatment process. [Extracted from the article]

A recent report from St. Louis, Missouri discusses the case of a 53-year-old paint salesman who experienced severe attacks of abdominal pain, nausea, vomiting, and diarrhea throughout his career. Traditional treatments were ineffective, but the patient was ultimately diagnosed with mast cell activation syndrome. Intravenous mast cell-targeted therapy and low-dose imatinib resulted in significant improvement, and the patient also made behavioral modifications to reduce symptoms triggered by paint fumes. This research highlights the importance of considering mast cell activation syndrome as a potential cause of these symptoms and suggests potential treatment options. [Extracted from the article]

A recent study conducted at the University of Ciencias Medicas examined the prognostic factors for survival in patients with gastrointestinal stromal tumors (GIST) who were treated with adjuvant imatinib therapy. GISTs are rare neoplasms of the gastrointestinal tract, and adjuvant therapy with imatinib has been shown to increase disease-free interval and overall survival. The study found that patients aged over 60 years, non-gastric tumor location, higher mitotic index, and positive surgical margins were independent prognostic factors associated with lower survival rates. The results of the study were similar to those reported internationally, making it the first Cuban report on the use of adjuvant imatinib in the real world. [Extracted from the article]

A recent study conducted at the University Hospital Erlangen examined the effects of imatinib treatment on the growth of pediatric patients with chronic myeloid leukemia (CML). The study analyzed 94 patients who had been treated with imatinib for over 12 months. The results showed that imatinib treatment led to a reduction in height, with more significant effects observed in prepubertal patients during the first year. However, by the second year, the effects were similar between prepubertal and pubertal patients. The study highlights the need for optimizing treatment strategies to ensure maximum growth potential in pediatric CML patients. [Extracted from the article]

A preprint abstract from biorxiv.org discusses a potential treatment strategy for metastatic ovarian cancer using a nanoformulation called Bola/IM. The nanoformulation, which encapsulates the drug imatinib, targets ovarian cancer stem cells and inhibits cancer cell survival, stemness, and metastasis. The study shows promising results in mouse models and patient-derived samples, and suggests that Bola/IM could be used as a targeted and potent treatment for metastatic ovarian cancer. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A recent study conducted at the University Clinic in Jena, Germany, explored the use of asciminib, a BCR-ABL1 inhibitor, as a potential treatment for newly diagnosed chronic myeloid leukemia (CML). The study compared asciminib to investigator-selected tyrosine kinase inhibitors (TKIs) and imatinib, and found that asciminib demonstrated superior efficacy and a favorable safety profile. The primary endpoint of major molecular response at week 48 was achieved by a higher percentage of patients in the asciminib group compared to the TKI group. Adverse events and discontinuation of treatment were also less frequent with asciminib. This research provides valuable insights into potential treatment options for patients with CML. [Extracted from the article]

A recent study conducted by researchers at the University of Utah has revealed new findings on chronic myeloid leukemia (CML). The study examined the treatment and overall survival rates of CML patients from 2004 to 2021, focusing on the availability of tyrosine kinase inhibitors (TKIs) as a treatment option. The researchers found that the introduction of TKIs has significantly improved survival rates for CML patients, particularly those with resistance or intolerance to previous treatments. However, the study also identified disparities in survival rates among underserved populations, including underinsured individuals and racial minority groups. The researchers emphasize the importance of continued advances in treatment and efforts to improve access to care in order to achieve equitable survival outcomes for all CML patients. [Extracted from the article]

A recent study conducted by researchers at Uppsala University in Sweden compared two different methods for predicting the exposure of tyrosine kinase inhibitors (TKIs) in pediatric patients. The study evaluated the performance of allometric scaling of population pharmacokinetic (popPK) models versus physiologically based pharmacokinetic (PBPK) models based on adult data. The researchers found that allometric scaling of popPK models was better suited for predicting TKI exposure in pediatric patients aged 2 years and older. However, both methods performed comparably in some instances. The study provides valuable insights for model development and pediatric dose selection. [Extracted from the article]

A study conducted at the University of Texas MD Anderson Cancer Center compared the effectiveness of two drugs, ponatinib and imatinib, in treating newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The study found that ponatinib, when combined with reduced-intensity chemotherapy, resulted in a higher rate of minimal residual disease (MRD)-negative complete remission compared to imatinib. The safety profiles of both drugs were comparable. This research provides valuable insights into the treatment of Ph+ ALL and offers potential options for patients. [Extracted from the article]